Supriya Peshin, Internal Medicine Resident Physician at Ballad Health, shared on LinkedIn:
“Publication Alert: Tarlatamab demonstrates promising real-world efficacy in previously treated small cell lung cancer.
A systematic review of a few studies reported response rates of 35–67%, with notable rates of CRS and ICANS. Larger prospective studies are needed to confirm its effectiveness and safety.”
Title: Real-World Effectiveness and Safety of Tarlatamab in Small Cell Lung Cancer: A Systematic Review
Authors: Supriya Peshin, Ehab Takrori,Bhavesh Mohan Lal, Konstantinos Arnaoutakis
You can also read: Small-Cell Lung Cancer (SCLC) Is Entering a Targeted Era: From Tarlatamab to ADCs, Radioconjugates, and Molecular Subtypes
